Visionary Ventures
Venture capitalNewport Beach · Series A–Late Stage · 13 people tracked
Investment thesis
Visionary Ventures believes that better information produces better investments and superior returns. It builds an advantage by partnering with Key Opinion Leaders (KOLs), industry experts, and strategic acquirers who source, vet, and advocate deals through a peer-review process. Beyond returns, the firm prioritizes backing companies that serve unmet or underserved markets and create broader societal impact. It seeks visionary, proven entrepreneurs turning ideas into market-leading businesses, focusing on the Series A to commercialization phase with target investments of $5M to $15M.
Source: firm website, verified Aug 3, 2026.
Team · 13 people
from the firm's website
What they invest in
from 11 of 16 portfolio companiesBiotech ×9Healthtech ×8Medical Devices ×6Digital Health ×1Longevity ×1
HQs:United States×9
Investments · 16 tracked
founders shown can be your intro pathRxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.
HealthtechMedical DevicesPasadena, US
Joseph Devivo(Director)James N. Adler(Director)Robert H. Grubbs(Director)Werner F. Wolfen(Director)D. Verne Sharma(Executive Officer, Director)Javier Perez-Sala(Director)
Co-investorsFlying L PartnersForesite CapitalH.I.G. CapitalH.I.G. HealthBridge PartnersLongitude CapitalRA Capital+1 more
Tarsus Rx is a pharmaceutical company developing treatments for diseases with high unmet need, with a lead product XDEMVY (lotilaner ophthalmic solution) approved by the FDA for Demodex blepharitis.
BiotechHealthtechMedical Devices
Bobak Azamian, MD, PhD(Founder)in
Co-investorsAPERTURE Venture PartnersFlying L PartnersFrazier Life SciencesVivo Capital
Iantrek develops micro-interventional ophthalmic surgical technologies focused on enhancing total outflow through the uveoscleral pathway to treat glaucoma.
BiotechHealthtechMedical DevicesElkins Park, US
Tsontcho Ianchulev(Executive Officer, Director)Sean Ianchulev(Founder & Chairman of the Board (CMO))Michael Haydin(Executive Officer)
BoardJeffry K Weinhuff(Director)Farrell Tyson(Director)Stephen Bloch(Director)in
Co-investorsaMoonCanaan PartnersCivilization Ventures Management, LlcFemHealth VenturesJSD Capital, LLCUS Venture Partners
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder & Chief Scientific Officer)David Esposito(Executive Officer, Director)Constance Chang(Executive Officer)John K Freshley(Executive Officer, Director)Jeffrey A Jamison(Executive Officer)David N Zacks(Executive Officer, Director)
Co-investorsExSight VenturesInvest MichiganNovartis Venture FundBios PartnersInFocus Capital Partners, LLCJohnson & Johnson Innovation – JJDC+3 more
Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space.
BiotechHealthtechMedical Devices
Co-investorsArboretum VenturesMaverick Ventures IsraelCatalio Capital ManagementJohnson & Johnson Innovation – JJDCLifeSci Venture PartnersSequoia Capital+1 more
Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.
BiotechDigital HealthDel Mar, US
Patrick Johnson(Executive Officer, Promoter)Mary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)
Co-investorsLongitude CapitalRA Capital
Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease.
BiotechHealthtechMedical DevicesSeattle, US
DAVID ROSTOV(Executive Officer)GREG KUNST(Executive Officer, Director)PATRICK LALLY(Director)JEANNETTE BANKES(Director)CHRISTINE MCCAULEY(Director)ARNAUD LACOSTE(Executive Officer)
Co-investorsDeerfield Management CompanyFlying L Partners
Co-investorsFlying L Partners
HealthtechReno, US
Tsontcho Ianchulev(Executive Officer, Director)Charles Warden(Director)Brian Walsh(Executive Officer, Director)Bruce J. Brumfield, Jr.(Director)Glenn Rockman(Director)Jim Mazzo(Director)
Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.
BiotechHealthtechLongevity
William Lowry(PhD)Christina Weng(Chief Medical Officer)Nathan Wheeler(Chief Operating Officer)Daniel Gil(PhD)
Co-investorsGV (Google Ventures)ARCH Venture PartnersHAWKTAILYK Bioventures
BiotechLos Angeles, US
William Edward Lowry(Director)Daniel Gil(Executive Officer, Director)Heather Christofk(Executive Officer)
BoardCathy Friedman(Director)
Co-investorsARCH Venture PartnersGV (Google Ventures)YK Bioventures
Co-investorsClarendon Fund Managers Ltd.ExSight Ventures
Co-investorsFlying L Partners
BiotechCopley, US
Kevin Hershfield(Executive Officer, Director)
BoardWilliam Link(Director)Jeffry Weinhuff(Director)Tyler Stowater(Director)Richard Heinick(Director)Steve Pazol(Director)
Co-investorsFlying L PartnersVersant Venture AIV Holdings
Exits · 2
IPOs and acquisitions across the tracked portfolioRxsightNASDAQ: RXSTTarsus PharmaceuticalsNASDAQ: TARS
Portfolio news
latest coverage across their companies
Aurion Biotech · regmednet.com · Aug 20, 2026
Rxsight · tipranks.com · Aug 12, 2026
Pelage · hairlosscure2020.com · Jul 26, 2026
Pelage Pharmaceuticals · hairlosscure2020.com · Jul 26, 2026
Iantrek · finsmes.com · Apr 29, 2026
Frequently asked questions
- How many investments has Visionary Ventures made?
- Visionary Ventures has 15 tracked investments.
- What stage does Visionary Ventures invest at?
- Visionary Ventures invests at the Series A, Series B, Growth, Late Stage stages.
- What is Visionary Ventures's typical check size?
- Visionary Ventures typically writes checks of $5M – $15M.
- What sectors does Visionary Ventures focus on?
- Visionary Ventures focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices, Sector Agnostic.
- Where is Visionary Ventures located?
- Visionary Ventures is headquartered in Newport Beach, US.
- Who does Visionary Ventures co-invest with?
- Visionary Ventures most often shares deals with Flying L Partners, ExSight Ventures, Longitude Capital, among 26 tracked co-investors.
Similar investors
MaRS is a Toronto-based innovation hub and accelerator that supports Canadian startups from pre-seed funding through international expansion, offering workspace, mentorship, investor and customer connections, and sector-focused programming.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
iNetworks is a private equity investment fund and advisory practice founded in 1999, focused on funding disruptive healthcare, life science, and technology companies while providing operational expertise and long-term partnership.
Portfolia operates venture funds designed by and for women, enabling members to invest collectively in innovative companies while learning together through curated content, founder access, and hands-on deal flow.